CRISPR Therapeutics (NASDAQ:CRSP) gains visibility as biotechnology activity aligns with broader movements across the Nasdaq ...

This year, gene-editing technology was customized to fix mutations in a single patient’s genes for the first time.

Bispecific antibodies bring multiple tumor-cell-killing mechanisms into play simultaneously. When a T cell is activated and ...

Casgevy, now a "national priority" drug, helped kids with sickle cell and thalassemia, results which may help toward a label ...

From rare diseases to chronic conditions, epigenetic editing unlocks new ways to control gene activity without altering the genetic code.

CRISPR Therapeutics (CRSP) shares have seen considerable movement over the past month, leaving investors assessing what might be driving sentiment around this gene editing pioneer. With no recent ...

Flashpoint Therapeutics, a biotechnology company pioneering a new class of structural nanomedicines, today congratulates its scientific co-founder, Professor Chad A. Mirkin, on being awarded the ...

The code of life is now editable and the question humanity must answer in the 2020s is not whether we can rewrite it—but whether we should, and for whom.

To compete at iGEM, a sort of science Olympics, teens at a Georgia high school set their sights on finding a better way to ...

When UC Berkeley biochemist Jennifer Doudna first began studying how bacteria fight virus infections, she had no idea it ...

Nearly three decades since the remarkable cloning of Dolly the sheep, it has all gone quiet on the human cloning front.

Scientists grew a microscopic fungus into a more efficient — and meat-like — edible protein by tweaking just two genes with ...